ZIIHERA

GrowthBsAb

zanidatamab-hrii

Jazz Pharmaceuticals

BLAINJECTIONINJECTABLEPriority Review

Approved

Nov 2024

Lifecycle

Growth

Competitive Pressure

30/100

Mechanism of Action

HER2-directed Antibody Interactions

Pharmacologic Class:

Bispecific HER2-directed Antibody

Company

Jazz Pharmaceuticals

External Resources

Full prescribing information

FDA approval history

Drug nomenclature & identifiers